NEUROCRINE BIOSCIENCES INC Amortization of Intangible Assets
NEUROCRINE BIOSCIENCES INC (NBIX) reported Amortization of Intangible Assets of $16.40 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfIntangibleAssets · last filed 2026-07-31
- NEUROCRINE BIOSCIENCES INC amortization of intangible assets for the quarter ending 2026-06-30 was $16.40M, a 1540.00% increase year-over-year.
- NEUROCRINE BIOSCIENCES INC amortization of intangible assets for the quarter ending 2026-03-31 was $100.00K, a 90.00% decline year-over-year.
- NEUROCRINE BIOSCIENCES INC amortization of intangible assets for the quarter ending 2025-12-31 was $1.10M, a 22.22% increase year-over-year.
- NEUROCRINE BIOSCIENCES INC amortization of intangible assets for the quarter ending 2025-09-30 was $1.00M, a 11.11% increase year-over-year.
- NEUROCRINE BIOSCIENCES INC amortization of intangible assets for fiscal 2025 was $4.10M, a 13.89% increase from fiscal 2024.
- NEUROCRINE BIOSCIENCES INC amortization of intangible assets for fiscal 2024 was $3.60M, a 2.86% increase from fiscal 2023.
- NEUROCRINE BIOSCIENCES INC amortization of intangible assets for fiscal 2023 was $3.50M, a 600.00% increase from fiscal 2022.
- NEUROCRINE BIOSCIENCES INC amortization of intangible assets for fiscal 2022 was $500.00K.
| Period end | Amortization of Intangible Assets 3 month | Amortization of Intangible Assets 6 month | Amortization of Intangible Assets 9 month | Amortization of Intangible Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | $16.40M 10-Q · filed 2026-07-31 | $16.50M 10-Q · filed 2026-07-31 | $17.60M derived: sum of 3 quarters · filed 2026-07-31 | $18.60M derived: sum of 4 quarters · filed 2026-07-31 |
| 2026-03-31 | $100.00K 10-Q · filed 2026-05-05 | $1.20M derived: sum of 2 quarters · filed 2026-05-05 | $2.20M derived: sum of 3 quarters · filed 2026-05-05 | $3.20M derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-12-31 | $1.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $2.10M derived: sum of 2 quarters · filed 2026-02-11 | $3.10M derived: sum of 3 quarters · filed 2026-07-31 | $4.10M 10-K · filed 2026-02-11 |
| 2025-09-30 | $1.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $2.00M derived: sum of 2 quarters · filed 2026-07-31 | $3.00M 10-Q · filed 2025-10-28 | $3.90M derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-06-30 | $1.00M 10-Q · filed 2026-07-31 | $2.00M 10-Q · filed 2026-07-31 | $2.90M derived: sum of 3 quarters · filed 2026-07-31 | $3.80M derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-03-31 | $1.00M 10-Q · filed 2026-05-05 | $1.90M derived: sum of 2 quarters · filed 2026-05-05 | $2.80M derived: sum of 3 quarters · filed 2026-05-05 | $3.70M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $900.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $1.80M derived: sum of 2 quarters · filed 2026-02-11 | $2.70M derived: sum of 3 quarters · filed 2026-02-11 | $3.60M 10-K · filed 2026-02-11 |
| 2024-09-30 | $900.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $1.80M derived: sum of 2 quarters · filed 2025-10-28 | $2.70M 10-Q · filed 2025-10-28 | $3.50M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-06-30 | $900.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-30 | $1.80M 10-Q · filed 2025-07-30 | $2.60M derived: sum of 3 quarters · filed 2026-02-11 | $3.50M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-03-31 | $900.00K 10-Q · filed 2025-05-05 | $1.70M derived: sum of 2 quarters · filed 2026-02-11 | $2.60M derived: sum of 3 quarters · filed 2026-02-11 | $3.50M derived: sum of 4 quarters · filed 2026-02-11 |
| 2023-12-31 | $800.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $1.70M derived: sum of 2 quarters · filed 2026-02-11 | $2.60M derived: sum of 3 quarters · filed 2026-02-11 | $3.50M 10-K · filed 2026-02-11 |
| 2023-09-30 | $900.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | $1.80M derived: sum of 2 quarters · filed 2024-10-30 | $2.70M 10-Q · filed 2024-10-30 | $3.20M derived: sum of 4 quarters · filed 2025-02-10 |
| 2023-06-30 | $900.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $1.80M 10-Q · filed 2024-08-01 | $2.30M derived: sum of 3 quarters · filed 2025-02-10 | $2.30M derived: sum of 4 quarters · filed 2025-02-10 |
| 2023-03-31 | $900.00K 10-Q · filed 2024-05-01 | $1.40M derived: sum of 2 quarters · filed 2025-02-10 | $1.40M derived: sum of 3 quarters · filed 2025-02-10 | $1.40M derived: sum of 4 quarters · filed 2025-02-10 |
| 2022-12-31 | $500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-10 | $500.00K derived: sum of 2 quarters · filed 2025-02-10 | $500.00K derived: sum of 3 quarters · filed 2025-02-10 | $500.00K 10-K · filed 2025-02-10 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-31 | $0.00 derived: sum of 2 quarters · filed 2023-10-31 | $0.00 10-Q · filed 2023-10-31 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-01 | $0.00 10-Q · filed 2023-08-01 | ||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-03 | |||
| 2021-12-31 | $0.00 10-K · filed 2024-02-09 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |